BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
While its reduced expression leads to a modest 14.2% decrease in lifespan under ad libitum fed conditions, it is essential for the longevity benefits of fasting
TIRO x MDS Multidisciplinary Seminars, US
Still, they also want to know what glutathione does, how the treatment is administered, and what realistic expectations are
Comparative in-vitro assessment of RV and KI loaded nanostructured lipid carriers (NLCs) individually and in combination on neuro-2a cell lines
Acknowledgements The authors thank Peng Cao from Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, for providing Nrf2 -knockout mice